Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01206270

Androgen for Leydig Cell Proliferation (ALCeP)

Androgen Treatment in Leydig Cell Proliferation

Sponsor: University of Roma La Sapienza

Conditions Hypergonadotropic Azospermia Hypergonadotropic Cryptozoospermia Hypergonadotropic Hypogonadism Klinefelter Syndrome

Interventions Castor Oil Testosterone undecanoate

Updated 6 times since 2017 Last updated: Sep 21, 2018 Started: Jun 30, 2009 Primary completion: Jun 30, 2017 Completion: Jun 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Hypergonadotropic Azospermia and Hypergonadotropic Cryptozoospermia and is currently completed. University of Roma La Sapienza leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Oct 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Oct 2018 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Roma La Sapienza

Data source: University of Roma La Sapienza

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy